2018 Congress of the Mexican Association of Oncological Urology

Genotypification and Polimorphirms of Single Nucleotide (SNP) Associated to Prostate Cancer Risk

Acapulco, GRO, Mexico (UroToday.com) Lucero Delgado Pastelín, with a masters degree in science, pointed out the importance of prompt diagnosis and management of prostate cancer. She explained how there is a big difference in mortality from prostate cancer between poor and rich countries, the former having a higher rate of deaths from prostate cancer, mainly because of worse preventive strategies. In Mexico prostate cancer is the leading cause of death in men, because of a malignancy. Cancer is multifactorial, and amongst the internal risk factors, infection with HPV has been associated with prostate cancer. In up to 53% of specimens with prostate cancer, HPV can be found. Some subtypes are especially dangerous: 16, 18, 31, 33 and 58. This virus leaves prints in cells which can be detected before developing cancer, so HPV detection is a useful prevention tool.

Genetics is another factor involved in prostate cancer, and according to this, individualized treatment is a worldwide tendency. There is a polymorphism, which is very common amongst Mexican men, RS10459592, and it has been found to cause a change in estrogenic hormones. This polymorphism makes an indivifual 2.3 times suceptible to prostate cancer. By knowing this, diagnosing the polymorphism can be a useful preventive tool, and will encourage earlier and more regular monitoring of prostate cancer.

How to evaluate for HPV and the afore mentioned polymorphism in a not so invasive manner? A special test called Kimera was developed in Mexico, it detects 15 subtypes of HPV and susceptibility for prostate cancer in 100cc of urine. Results are given in an allelic discrimination graph.

She then explained how one person can have up to 7 different types of HPV at the same time, this can give us an idea on how healthy the immune system is. Finally, she emphasized the importance of the HPV subtype, since some are more oncogenic, for example 16, which is 9 times more oncogenic than 18. All of these strategies will help us decide which individuals are at highest risk for developing prostate cancer, and manage them appropriately.

Presented by: Lucero Delgado Pastelín

Written by: Paulina Bueno Garcia Reyes, MD, medical writer for UroToday.com and Ashish Kamat, MD, Professor of Urology and Director of Urologic Oncology Fellowship at M.D. Anderson Cancer Center, at the Mexican Urologic Oncology Association Meeting - July 26 - 28, 2018
email news signup